Align Technology, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this filing reports full-year results; it does not provide a complete standalone fourth-quarter income statement.
Business context
Align designs, manufactures and sells Invisalign clear aligners and Vivera retainers, iTero intraoral scanners and services, and exocad CAD/CAM software. Clear Aligner generated approximately 82% of FY2022 revenue; Systems and Services generated the balance. The company’s strategy centers on international expansion, general-practitioner adoption, patient demand and conversion, and higher orthodontist utilization.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net revenue | $3,734.6 million | $3,952.6 million |
| Gross profit / margin | $2,633.8 million / 70.5% | $2,935.4 million / 74.3% |
| Operating income / margin | $642.6 million / 17.2% | $976.4 million / 24.7% |
| Net income | $361.6 million | $772.0 million |
| Diluted earnings per share | $4.61 | $9.69 |
| Operating cash flow | $568.7 million | $1,172.5 million |
| Capital expenditures | $291.9 million | $401.1 million |
| Cash, cash equivalents and marketable securities at year-end | $1,041.6 million | $1,296.7 million |
- Revenue declined 5.5%. Clear Aligner revenue fell 5.4% to $3,072.6 million; Systems and Services revenue fell 6.2% to $662.1 million.
- Clear Aligner case shipments decreased 7.4% to 2.36 million. Total Invisalign utilization declined to 18.9 cases per doctor from 20.8.
- Cost of revenue rose to 29.5% of revenue from 25.7%; the overall gross margin contracted 3.8 percentage points.
- Cash from operations decreased substantially. Working-capital movements included higher deferred revenue (+$241.9 million) and inventory (+$130.1 million), partly offset by lower accrued and other long-term liabilities.
- No borrowings were outstanding under the $300 million unsecured revolving credit facility at year-end; the facility matures in December 2027. The filing reports no material off-balance-sheet arrangements.
Changes versus the prior year
- Revenue and volumes weakened amid foreign-exchange headwinds, lower scanner sales, reduced consumer and dental-practice demand, and COVID-related shutdowns in China. International Clear Aligner revenue declined 10.0%, including an estimated $150.6 million revenue reduction from unfavorable currency movements.
- Clear Aligner Americas revenue fell 5.6%, principally due to lower case volume; higher average selling price partially offset the decline. Non-case revenue, mainly retainers, increased 30.0%.
- Systems and Services revenue declined as scanner sales and scanner average selling prices weakened; higher service revenue partially offset the decrease.
- Margin pressure reflected a higher mix of additional aligners, elevated freight costs and spending to ramp the Poland manufacturing facility. Systems and Services margins also faced lower scanner production volumes and pricing.
- Operating income fell 34.2%, and net income fell 53.2%. The effective tax rate increased to 39.6% from 23.7%, partly due to lower earnings in low-tax jurisdictions and U.S. tax treatment of research and development costs.
- FY2021 included a $43.4 million gain from the SmileDirectClub arbitration award; FY2022 did not. FY2020 net income was unusually elevated by a $1,493.5 million one-time tax benefit related to an intellectual-property transfer.
Outlook, risks and unusual items
- The filing gives no specific revenue or earnings guidance. Management expects international revenue to grow faster than Americas revenue over the longer term, while acknowledging uncertain macroeconomic and regional demand conditions.
- Management expects capital expenditures to exceed $200 million over the next 12 months, primarily for facilities and manufacturing capacity. It plans continued investment in R&D, treatment planning, sales and marketing, while citing cost controls, pricing actions and slower hiring.
- Key uncertainties include inflation, higher interest rates, currency fluctuations, recession risk, competitive pricing and products, changing consumer demand, and continued COVID-19 effects in China. Russia-Ukraine-related sanctions, reduced Russian operations and relocation of R&D personnel create additional operational and geopolitical risks.
- Supply concentration is material: the company relies on single or limited sources for key aligner resin and polymer, scanner components, and manufacturing equipment. Freight costs and production interruptions could affect margins and fulfillment.
- In Q4 2022, Align initiated a restructuring intended to improve efficiency; it recorded $11.5 million of restructuring and other charges for the year, including severance, lease termination costs and asset impairments. The plan was expected to be completed in the first half of 2023.
- In the SDC arbitration, an October 2022 interim award found SDC had breached the supply agreement and awarded damages to Align, but the company said it would recognize amounts only after confirmation of a final award. SDC’s additional counterclaim remained unresolved.
- Antitrust class actions were pending, with trials scheduled for 2024. The company said it could not estimate the likelihood or range of loss. The 2020 securities class action was dismissed and ultimately resolved in Align’s favor.
- Management identified clear-aligner revenue allocation and estimates of additional-aligner usage as a critical audit matter. The auditor gave unqualified opinions on the financial statements and internal control; management and the auditor reported internal control over financial reporting effective as of year-end.
- After year-end, the board authorized a new $1.0 billion repurchase plan, and Align entered a $250 million accelerated repurchase agreement. The 1% U.S. excise tax on stock repurchases became effective in 2023.
Important facts for investors to verify
- Whether case volumes, doctor utilization and scanner sales stabilize, particularly in China and international markets.
- How much revenue and margin pressure persists from foreign exchange, promotions, product mix, freight, and the Poland facility ramp.
- Whether operating cash flow recovers as inventory and other working-capital needs normalize, and how the planned capital spending is funded.
- The final outcome and accounting treatment of the SDC arbitration and the potential exposure from the pending antitrust litigation.
- How Align’s $1.0 billion repurchase authorization, the $250 million ASR and the repurchase excise tax affect cash, share count and capital allocation.
- Whether the large deferred-tax asset remains realizable and how tax law changes and uncertain tax positions affect future effective tax rates.